Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US. The FDA sent the Danish ...

Novo Nordisk said that if approved for use, insulin icodec would reduce the number of basal insulin injections needed per year for type 2 diabetics from 365 to 52, a significant reduction in ...

Small molecules with big potential The two drugs used in this study are already approved to treat rare cancers. Tazemetostat, known under the brand name Tazverik, was approved by the U.S. FDA in ...

Novo Nordisk’s insulin brand Mixtard will continue to be available in vials, the Danish healthcare company clarified, even as it phases out its penfill. The penfill is being phased out as part ...

The board voted to add their name to a lawsuit alleging that insulin is unfairly overpriced in the United States at their March 18 meeting. If successful, the suit could result in a payout of ...

After undergoing offseason surgery to repair a labrum tear in his left shoulder, Shohei Ohtani worked on modifying his slide during the spring to prevent future injuries. The two-way star is ...

Austin Riley was mocked online for his less-than-graceful slide into home plate against the St. Louis Cardinals on Monday, even though it set the stage for the Atlanta Braves' victory. Austin ...

Irving-based international nonprofit health system CHRISTUS Health broke ground this week on a new hospital in Cabo San Lucas, Mexico to meet the needs of the growing tourist destination.

U.S. stocks closed higher, recovering Monday's losses on hopes for trade deals. Vice President JD Vance said the U.S. has made “significant progress” toward a bilateral trade deal following ...

Thirty-seven-year-old Nupur Lalvani, who has been living with Type 1 diabetes since the age of eight, was dependent on insulin pens and had of late been a regular user of Novo Nordisk’s largest ...

That’s what some are wondering after Novo Nordisk has said it is discontinuing selling its insulin brand in India. The decision from the Danish company could shake up the insulin market, say experts.